Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWATM214 in advanced hepatocellular carcinoma
NCT05926726Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JWATM214 in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Primary endpoints: Treatment-related adverse events at 2 years, Dose-limiting toxicities at 28 days and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
JWATM214
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05926726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926726.